ALA 15.6% 18.5¢ arovella therapeutics limited

December deal, page-2

  1. 340 Posts.
    lightbulb Created with Sketch. 20
    seems like a bit of a spat by the market. small caps never meet their timelines so no need for mass resignation of management, or else there would be no small caps on the asx at all.
    The market seems to be over-emphasizing the importance of artimist. If you read the last research report (commissioned by SUDA) they only attribute 2 cents per share to artimist. The big guns are the oromist products and this is why i see today as a great buying opportunity for anyone who can see 6 months ahead.
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.